12 unchanged sentences
Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.
−Removed: Securities Authorized for Issuance under Equity Compensation Plans
−Removed: The information required by this item with respect to our equity compensation plans is incorporated by reference to our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, or the Proxy Statement.
−Removed: Index to Financial Statements
+Added: Index to Financial Statement s
+Added: Stock Performance Graph
+Added: The graph below shows a comparison, from January 31, 2020 (the date our common stock commenced trading on Nasdaq) through December 31, 2024, of the cumulative total return to stockholders of our common stock relative to the Nasdaq Composite Index (^IXIC) and the Nasdaq Biotechnology Index (^NBI).
+Added: The graph assumes that $100 was invested in each of our common stock, the Nasdaq Composite and the Nasdaq Biotechnology at their respective closing prices on January 31, 2020 and assumes reinvestment of gross dividends.
+Added: The stock price performance shown in the graph represents past performance and should not be considered an indication of future stock price performance.
+Added: This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
+Added: Cumulative Total Return Comparison
+Added: (Inception) 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
+Added: Arcutis Biotherapeutics, Inc.
+Added: $100.00 $129.04 $95.14 $67.89 $14.82 $63.90
+Added: Nasdaq Composite Index $100.00 $140.84 $170.97 $114.38 $164.04 $211.03
+Added: Nasdaq Biotechnology Index $100.00 $133.14 $132.30 $117.87 $122.27 $120.60
+Added: Index to Financial Statement s
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.